Media Releases Financial Reports Presen-tations 08/27/2008     Basel / Walkersville, 27 August 2008 Lonza announces the availability of primary Clonetics® Adult Normal Human Epidermal Melanocytes. These are highly characterized cells for use in diverse applications in dermal research including malignant melanoma, dermal disorders, toxicology, pigmentation and cosmetic studies. Malignant melanoma is one for the most aggressive forms of cancer and rates of incidence continue to grow at an alarming rate. As expected, there is considerable interest in research pertaining to malignant melanoma and other skin disorders that occur more frequently in adults. In many cases, epidermal melanocytes which have been subjected to a variety of environmental exposures such as UV damage, wounds, burns and various pathogenic insults offer researchers a cell type that yields more relevant and meaningful experimental results. Clonetics® Adult Melanocytes are available as cryopreserved amps, proliferating plates, or proliferating flasks. For more information on this product or to place an order, please go to: www.lonza.com. For technical service please call +1 800-638-8174. About Lonza Lonza is one of the world's leading suppliers to the pharmaceutical, healthcare and life science industries. Its products and services span its customers’ needs from research to final product manufacture. Lonza is the global leader in the production and support of active pharmaceutical ingredients both chemically as well as biotechnologically. Biopharmaceuticals are one of the key growth drivers of the pharmaceutical and biotechnology industries. Lonza has strong capabilities in large and small molecules, peptides, amino acids and niche bioproducts which play an important role in the development of novel medicines and healthcare products. Lonza is a leader in cell-based research, endotoxin detection and cell therapy manufacturing. Lonza is also a leading provider of value chemical and biotech ingredients to the nutrition, hygiene, preservation, agro and personal care markets. Lonza is headquartered in Basel, Switzerland and is listed on the SWX Swiss Exchange. In 2007, Lonza had sales of CHF 2.87 billion. Further information can be found at www.lonza.com. For further Information: Lonza: Head Corporate Communications Janet White Tel +41 61 316 8566 Fax +41 61 316 9566 janet.white@lonza.com Media Relations Dominik Werner Tel +41 61 316 8798 Fax +41 61 316 9798 dominik.werner@lonza.com Investor Relations Alexandre Pasini Tel +41 61 316 8835 Fax +41 61 316 9835 alexandre.pasini@lonza.com Mark Herb Product Manager – Clonetics® Tel +1 301-898-7025, ext. 2633 Fax: +1 301-845-7900 mark.herb@lonza.com